FDA grants CytoDyn fast track designation for leronlimab (PRO 140) in metastatic triple-negative breast cancer, an unmet medical need

7 May 2019 - CytoDyn today announced that the U.S. FDA has granted fast track designation to leronlimab (PRO140) for ...

Read more →

RedHill Biopharma submits new drug application for Talicia for H. pylori Infection

7 May 2019 - RedHill Biopharma today announced that, following a positive pre-NDA meeting held recently with the U.S. FDA, ...

Read more →

In a crafty move, FDA may have found a way to dampen controversy over a $375,000 rare disease drug

6 May 2019 - The FDA just added an unexpected twist to a simmering controversy over a rare disease drug ...

Read more →

Zynerba Pharmaceuticals receives fast track designation for Zygel for the treatment of behavioural symptoms associated with Fragile X syndrome

6 May 2019 - Enrolment progressing in pivotal CONNECT-FX trial of Zygel in Fragile X syndrome, with data expected in the ...

Read more →

Savara announces Molgradex received fast track designation by FDA for treatment of auto-immune pulmonary alveolar proteinosis

6 May 2019 - Savara today announced that the U.S. FDA granted fast track designation for Molgradex, an inhaled formulation ...

Read more →

FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare auto-immune disorder

6 May 2019 - The U.S. FDA today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients ...

Read more →

Pfizer gets U.S. approval for $225,000/year heart drug

6 May 2019 - The U.S. FDA on Monday approved Pfizer's oral drug, tafamidis, to treat a rare and fatal heart ...

Read more →

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin‑mediated amyloidosis

6 May 2019 - On May 3, the U.S. FDA approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment ...

Read more →

Esperion announces U.S. FDA acceptance of new drug applications for both bempedoic acid and the bempedoic acid with ezetimibe combination tablet for filing and regulatory review

5 May 2019 - 21 February 2020 PDUFA target date goal for bempedoic acid and 26 February 2020 PDUFA target ...

Read more →

FDA approves Genentech's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neo-adjuvant treatment

3 May 2019 - Application approved under FDA’s real-time oncology review pilot program. ...

Read more →

Qternmet XR approved in the US for the treatment of type 2 diabetes

3 May 2019 - The US FDA has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as ...

Read more →

Acacia Pharma receives complete response letter from FDA for Barhemsys

3 May 2019 - Acacia Pharma announces that it has received a second complete response letter from the US FDA ...

Read more →

Agios announces FDA approval of supplemental new drug application for Tibsovo as monotherapy for newly diagnosed adult patients with IDH1 mutant acute myeloid leukaemia not eligible for intensive chemotherapy

2 May 2019 - Approval based on 28 newly diagnosed patients from Phase 1 study of Tibsovo in advanced haematologic ...

Read more →

Using instrumental variables to address bias from unobserved confounders

2 May 2019 - Randomised clinical trials are considered the most reliable source of evidence for the effects of medical interventions, ...

Read more →

Pharmaceutical protections in U.S. trade deals — what do Americans get in return?

1 May 2019 - U.S. trade deals increasingly include terms affecting the approval process and availability of medicines.  ...

Read more →